5 completed, 4 terminated, 1 withdrawn. 8 Phase 2, 5 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Terminated 4, Completed 3, Withdrawn 1 |
| Phase 1 | 5 | Terminated 3, Completed 2 |
| Phase 3 | 2 | Completed 2 |
Follow zalutumumab: new trials by email Literature Review of zalutumumab trials Research Report on zalutumumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Neck (SCCHN) zalutumumab - Head and Neck Cancer | Phase 1 / Phase 2 | Completed | Genmab | 31 | 2010-03-01 | 2023-08-03 |
| Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients Ineligible for Platinum Based Chemotherapy Zalutumumab - Head and Neck Cancer, Squamous Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Genmab | 8 | 2008-09-01 | 2023-08-03 |
| Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Colorectal Cancer Zalutumumab - Colorectal Cancer | Phase 1 / Phase 2 | Terminated | Genmab | 9 | 2008-04-01 | 2023-07-18 |
| Zalutumumab in Non-curable Patients With SCCHN Zalutumumab - Head and Neck Cancer, Squamous Cell Cancer | Phase 2 | Completed | Genmab | 90 | 2008-01-01 | 2023-08-03 |
| DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC Radiotherapy, Zalutumumab - Cancer of the Head and Neck | Phase 3 | Completed | Danish Head and Neck Cancer Group | 619 | 2007-11-01 | 2016-11-25 |
| Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer Zalutumumab, Induction chemotherapy, Radiotherapy - Non Small Cell Lung Cancer | Phase 2 | Terminated | Genmab | 13 | 2007-04-01 | 2011-12-06 |
| Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer zalutumumab, cisplatin, Radiotherapy - Head and Neck Cancer, Squamous Cell Cancer | Phase 1 / Phase 2 | Terminated | Genmab | 30 | 2006-12-01 | 2011-12-23 |
| Zalutumumab in Patients With Non-curable Head and Neck Cancer Zalutumumab, Control - Head and Neck Cancer, Squamous Cell Cancer | Phase 3 | Completed | Genmab | 286 | 2006-11-01 | 2013-10-15 |
| Zalutumumab in Head and Neck Cancer Zalutumumab - Head and Neck Neoplasms | Phase 1 / Phase 2 | Completed | Genmab | 28 | 2003-12-01 | 2023-06-28 |
| Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors zalutumumab - Non-small Cell Lung Cancer | Phase 2 | Withdrawn | Genmab | 2011-10-10 |
Head and Neck Neoplasms (7) · Neoplasms, Squamous Cell (3) · Carcinoma, Non-Small-Cell Lung (2) · Squamous Cell Carcinoma of Head and Neck (2) · Carcinoma, Squamous Cell (1) · Colorectal Neoplasms (1)
Genmab (9) · Danish Head and Neck Cancer Group (1)
Belgium (6) · France (4) · United Kingdom (4) · Sweden (3) · United States (3) · Denmark (2) · Hungary (2) · Netherlands (2) · Slovakia (2) · Austria (1) · Brazil (1) · Canada (1) · Chile (1) · Colombia (1) · Czechia (1)
Hassan Aladdin, ICTM (1) · Jean-Pascal Machiels, MD, PhD (1) · Jens Overgaard, Prof. MD (1) · Steen Lisby, MD (1) · Steen Lisby, MD, PHD (1) · Vincent Gregoire, MD professor (1)